🕒 Last update: loading…21/11/2026

Stock COMPASS Pathways plc CMPS

COMPASS Pathways plc — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2020 → 2021: -53.61%

Price change 2021 → 2022: -63.67%

Price change 2022 → 2023: 8.97%

Price change 2023 → 2024: -56.80%

Price change 2024 → 2025: 82.54%

Price change 2025 → 2026: 63.19%

Price change 2026 (year to date): 71.91%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Negative or zero equity.

P/E (Price/Earnings)

P/E ratio: -3.56

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 25.87% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
COMPASS Pathways plc–––🔒
BioGaia AB (publ)32.70.01+13.3 %–
Clariane SE611.52.16+12.4 %–
Nutex Health, Inc.6.91.07+54.6 %–
Gerresheimer AG31.71.48+5.6 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Accounts and financial health

Balance sheet and cash flow published by COMPASS Pathways plc over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-2.05
risk zone (below 1.81)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
1.47 x
moderate debt
Fiscal year20212022202320242025
Cash and investments273 m143 m220 m165 m150 m
Total Debt3.6 m1.9 m33.0 m32.2 m20.9 m
Net Debt-270 m-141 m-187 m-133 m-129 m
Equity284 m181 m226 m155 m-52.8 m
Total assets301 m197 m276 m214 m210 m
Operating cash flow-67.7 m-105 m-97.4 m-119 m-157 m
Investments (capex)334,000596,00066,00000
Free cash-flow-68.1 m-106 m-97.4 m-119 m-157 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-2.06 x
Price / book value8.45 x
Return on Equity (ROE)-212.8 %
Return on Invested Capital (ROIC)-99.3 %
Net margin0.0 %
Debt / equity0.38 x
Current ratio1.50 x
Interest coverage-35.38 x
Free cash-flow yield-14.5 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

COMPASS Pathways plc compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
COMPASS Pathways plc1.3 bnn/a0.0 %
MapLight Therapeutics, Inc. MPLT309 mn/a0.0 %
Rapport Therapeutics, Inc. Common Stock RAPP1.3 bnn/a0.0 %
Harmony Biosciences Holdings, Inc. HRMY2.0 bn11.018.3 %
Minerva Neurosciences, Inc. NERV115 mn/a0.0 %
LB Pharmaceuticals Inc Common Stock LBRX1.4 bnn/a0.0 %
GH Research PLC GHRS1.3 bnn/a0.0 %
ACADIA Pharmaceuticals Inc. ACAD3.2 bn8.436.5 %
Praxis Precision Medicines, Inc. PRAX9.2 bnn/a0.0 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering COMPASS Pathways plc publish: ratings, price targets and earnings forecasts.

Majority rating
buy
16 analysts

Breakdown of ratings

strong buy 0buy 15hold 1sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 5 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in COMPASS Pathways plc.

Free float
98.4 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
depositary receipt (ADR)
Listing exchange
Nasdaq
IPO: 18/09/2020
ISIN code
US20451W1018
Workforce
166
full-time employees
Chief executive
Kabir Kumar Nath

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about COMPASS Pathways plc

What is the COMPASS Pathways plc share price?

Latest recorded price: 9.01 USD on 13/11/2026, for a market cap of 1.3 bn USD.

What do analysts say about COMPASS Pathways plc?

Out of 16 analysts: 15 buy or strong buy, 1 hold, 0 sell or strong sell.

Is COMPASS Pathways plc stock eligible for the French PEA?

No: this listing is a depositary receipt (ADR), excluded from the PEA.

How many employees does COMPASS Pathways plc have?

166 full-time employees according to the latest published profile.

Who runs COMPASS Pathways plc?

Kabir Kumar Nath is the company's chief executive.

07

Similar stocks